Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use MENVEO safely and effectively. See full prescribing information for MENVEO.MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] solution for injection, for intramuscular useInitial U.S. Approval: 2010
Medication labelWhy this: Advisory · dailymed-other
MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.
- generic_name
- meningococcal (groups a, c, y and w-135) oligosaccharide diphtheria crm197 conjugate vaccine
- brand_name
- MenA vaccine, MenC, Y, W-135 vaccine
- product_names
- Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, MenA vaccine, MenC, Y, W-135 vaccine
- ndc
- 58160-955, 58160-955-09, 58160-958, 58160-958-01, 58160-959, 58160-959-01, 58160-827, 58160-827-03, 58160-827-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en